CAS · 25812-30-0
Product Overview
Gemfibrozil is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Grade: | USP |
|---|---|
| Appearance: | White crystalline powder |
| Assay, on anhydrous basis: | 98.0% ~ 102.0% |
| Identification A: | The sample IR absorption spectrum should match the reference standard |
| Identification B: | The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay |
| Water: | 0.25% max |
| Related compound A: | 0.1% max |
| Any other individual impurity: | 0.08% max |
| Total impurities: | 0.5% max |
| Residual solvents - Tetrahydrofuran: | 720 ppm max |
| Residual solvents - Ethyl formate: | 5000 ppm max |
Applications
1. Treatment of Hyperlipidemia
● Gemfibrozil is used to lower elevated serum triglycerides (hypertriglyceridemia) and increase HDL cholesterol levels (the "good" cholesterol).
● It is especially effective in type IV and type V hyperlipoproteinemia, where triglycerides are significantly elevated.
● Often prescribed to patients who are at risk of pancreatitis due to very high triglyceride levels.
2. Prevention of Cardiovascular Events
● Gemfibrozil may reduce the risk of coronary heart disease (CHD) in patients with low HDL cholesterol and high triglyceride levels, particularly those who cannot tolerate statins or need combination therapy.
● In some studies (e.g., Helsinki Heart Study), it has been shown to lower the risk of non-fatal myocardial infarctions.
3.Mechanism of Action
Gemfibrozil丨25812-30-0 activates PPARα receptors, which in turn regulate genes involved in lipid metabolism:
● Increases activity of lipoprotein lipase (LPL), enhancing triglyceride breakdown.
● Reduces hepatic secretion of very-low-density lipoprotein (VLDL).
● Promotes removal of LDL particles from the blood.
● Enhances synthesis of apolipoproteins A-I and A-II, thereby increasing HDL production.
Benefits
1. Potent Triglyceride Lowering Agent
● Reduces serum triglycerides by 30–60% in most cases.
● Particularly useful in patients with diabetes, metabolic syndrome, or genetic lipid disorders.
2. Increases HDL Cholesterol
● Typically raises HDL levels by 10–20%, which is beneficial for cardiovascular protection.
3. Improves Postprandial Lipid Profiles
● Reduces the rise in blood triglycerides after meals, which is a predictor of atherosclerosis and cardiovascular events.
4. Synergistic with Other Lipid-Lowering Therapies
● Can be used in combination with statins or omega-3 fatty acids for patients with mixed dyslipidemia, under medical supervision.
● However, caution is required to avoid increased risk of myopathy or rhabdomyolysis, especially when combined with statins.
Other Notable Applications
1. Research Use
● Studied in models of inflammation, insulin resistance, and oxidative stress, due to its PPAR-agonist activity.
● Investigated for potential neuroprotective and anti-cancer effects, although not yet clinically established for these uses.
2. Potential in Rare Lipid Disorders
● Used off-label in some rare genetic lipid disorders like familial combined hyperlipidemia or familial dysbetalipoproteinemia.
Conclusion
Gemfibrozil丨25812-30-0 is a clinically established lipid-lowering drug widely used to treat high triglycerides and low HDL cholesterol, especially in patients at risk of cardiovascular disease or pancreatitis. With its strong triglyceride-lowering effects and ability to enhance HDL levels, it remains an important therapeutic option in lipid management, particularly when statins are contraindicated or as part of combination therapy in complex cases. Proper monitoring and patient selection are key to maximizing benefits and minimizing risks.
Previous
Next
Conclusion
A concise summary and suitability assessment for this product is available on request. Contact our team to discuss whether it fits your process and quality requirements.